FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY

Renoux F, Stellato M, Vogetseder A, Huang R, Subramaniam A, Blyszczuk P, Distler J, Kania G, Boyman O, Distler O (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 1065-1065

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

Event location: Madrid ES

DOI: 10.1136/annrheumdis-2019-eular.2841

Authors with CRIS profile

Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

Sanofi Genzyme US United States (USA) (US) Universitätsspital Zürich (USZ) CH Switzerland (CH) Luzerner Kantonsspital (LUKS) CH Switzerland (CH)

How to cite

APA:

Renoux, F., Stellato, M., Vogetseder, A., Huang, R., Subramaniam, A., Blyszczuk, P.,... Distler, O. (2019). FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1065-1065). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:

Renoux, Florian, et al. "FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 1065-1065.

BibTeX: Download